Ceva Santé Animale (Ceva) and ProBioGen have announced the signature of a multi-product license agreement for the use of ProBioGen’s AGE1.CR avian cell line in the industrial production of viral animal vaccines.
In a preceding pilot study Ceva evaluated the technology, which allows cells to grow rapidly and in high cell densities in ProBioGen’s proprietary chemically defined medium. Master cell banking for one viral vaccine strain has been completed and further development projects are underway.
Volker Sandig, Chief Scientific Officer of ProBioGen, is convinced that, “this agreement is the result of an excellent collaboration and is based on a mutual focus on technologically optimised biopharmaceutical manufacturing. We are pleased that Ceva as an expert vaccine producer decided to work with us on our AGE1.CR cell line.”
Marc Prikazsky, Ceva’s Chairman and CEO said “This type of scientific and industrial partnership with ProBioGen is an excellent example of how we hope to develop collaboration with genuinely innovative partners.”
An undisclosed number of animal vaccines are to be evaluated on the AGE1.CR cell line. The commercial license includes milestone and royalty payments. Financial details were not disclosed.